glp-1 class drugs Agonists Explained: Definition, How They Work, Side Effects Glp-1 Analogues Market Size, Share

Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation

Semaglutide, liraglutide and dulaglutide are GLP-1RAs, whereas tirzepatide is a dual GIP/GLP-1RA

In other studies, GLP-1RA addition did not increase the risk of hypoglycemia

Their efficacy though, both in terms of inhibiting plasma DPP-4 activity and as antidiabetic agents, appears to be similar [44]

However, the price differential between research peptides and pharmaceutical products will persist

Oral GLP-1 Approaches Commercial Inflection by 2028 GLP-1 Weight Loss Drug Market Revenue Share, CAGR, and Primary Drivers by Route 2026 Subcutaneous injectable administration commands 81.7% GLP-1 market revenue share in 2026 as the weekly autoinjector format delivers clinical efficacy, dose consistency, and patient convenience superior to daily injectable alternatives